Calliditas Therapeutics AB (publ) (Calliditas) has completed a directed share issue. The issue will raise proceeds to Calliditas of approximately SEK 210 million before transaction costs.

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. 

Calliditas intends to use the net proceeds from the issue for expansion of ongoing clinical development including new studies, acceleration of activities to build pipeline and for general corporate purposes. Calliditas is listed on Nasdaq Stockholm.

Carnegie Investment Bank and Zonda Partners acted as Joint Bookrunners in connection to the directed share issue. Baker McKenzie acted as legal adviser to the Joint Bookrunners as to Swedish and US law. Baker McKenzie’s team mainly consisted of Joakim Falkner, Henric Roth from the Stockholm office and Megan Schellinger from the London office.

Explore Our Newsroom